The rise of drugs like Ozempic, Mounjaro and Wegovy has already transformed the treatment of diabetes and obesity. Originally designed to regulate blood sugar and appetite, these GLP-1 receptor agonists became globally popular after patients experienced significant weight loss. Now, emerging research suggests these medications may offer another major benefit — reducing the risk of cancer progression and recurrence.
According to multiple new studies, patients taking GLP-1 drugs showed lower rates of tumour growth, reduced cancer progression, and improved survival outcomes in certain cancers, particularly breast, lung, colorectal and liver cancers. While researchers caution that more clinical trials are still needed, the findings are generating excitement across the medical community.
Studies Suggest Lower Cancer Progression Rates
One of the major studies conducted by the Cleveland Clinic Cancer Institute tracked more than 10,000 patients with early-stage cancers who began using GLP-1 drugs shortly after diagnosis. Researchers compared their outcomes with patients taking other diabetes medications and found that cancer spread was less common among those using GLP-1 therapies.
Another study focusing on lung cancer patients reported that only around 10 per cent of GLP-1 users experienced disease progression, compared to 22 per cent among patients not taking the drugs. Similar trends were seen in breast cancer cases, where tumour progression rates were significantly lower among GLP-1 users.
Researchers also observed reduced progression risks in colorectal and liver cancers, raising hopes that these medications may have broader anti-cancer effects.
Breast Cancer Research Shows Encouraging Survival Benefits
Separate studies examining breast cancer delivered especially encouraging results. Researchers at the University of Texas MD Anderson Cancer Center analysed data from over 137,000 breast cancer patients and found that more than 95 per cent of patients taking GLP-1 medications were still alive after five years. Among non-users, the survival rate stood at approximately 89.5 per cent.
Another study by the University of Pennsylvania examined nearly 95,000 women undergoing breast imaging. It found that women who had used GLP-1 drugs were nearly 25 per cent less likely to develop breast cancer, even after accounting for factors like age, body weight and existing health risks.
These findings have sparked growing interest in whether GLP-1 medications could eventually play a role in cancer prevention strategies.
Scientists Still Unsure How The Drugs Affect Cancer Cells
Despite the promising results, scientists say it remains unclear exactly how these medications may be influencing cancer biology. One theory suggests that the benefits are indirect — the drugs improve metabolic health and reduce obesity, both of which are strongly linked to lower cancer risk.
Another possibility is that GLP-1 receptors appear on the surface of some tumour cells, meaning the medications may directly interact with cancer-related biological pathways. Researchers believe this could potentially slow tumour growth or reduce cancer spread.
However, experts stress that these studies are observational and not specifically designed to prove cause and effect. Factors such as better healthcare access among GLP-1 users may also influence outcomes.
More Research Needed Before Clinical Use In Cancer Treatment
While the findings are encouraging, pharmaceutical companies like Novo Nordisk and Eli Lilly and Company are not currently conducting formal cancer-treatment trials using these medications. Medical experts say randomised clinical studies will be necessary before GLP-1 drugs can be recommended as part of cancer therapy or prevention.
Still, the early evidence has opened an important new area of research. As scientists continue exploring the long-term effects of GLP-1 medications, these drugs may eventually reshape not just obesity treatment, but also cancer care and prevention in the years ahead.